Eeva™ Continued Access Study: Assessing the Usability of Eeva in a Clinical Setting
CAS
Eeva Continued Access Study.
1 other identifier
observational
31
1 country
3
Brief Summary
User questionnaire of Eeva System usability and reports of device malfunctions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jun 2012
Shorter than P25 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2012
CompletedFirst Submitted
Initial submission to the registry
June 8, 2012
CompletedFirst Posted
Study publicly available on registry
June 13, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2013
CompletedJanuary 13, 2014
January 1, 2014
8 months
June 8, 2012
January 9, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
User questionnaire of Eeva System usability and reports of device malfunctions.
Participants will be followed through ongoing pregnancy, at approximately 10-12 weeks gestational age.
Study Arms (1)
Women undergoing IVF treatment
Women undergoing IVF treatment
Eligibility Criteria
Women in the United States who undergo IVF treatment and imaging of their embryos with Eeva.
You may qualify if:
- Women undergoing fresh in vitro fertilization treatment using their own eggs or donor eggs
- Subject is ≥ 18 and ≤ 40 years of age.
- Subject has basal antral follicle count (AFC) ≥ 8 prior to stimulation cycle.
- Fertilization using only ejaculated sperm (fresh or frozen) - no surgically retrieved sperm.
- Subject has ≥ 5 normally fertilized eggs (2 PN)
- Willing to have all 2PN embryos monitored by Eeva
- Willing to comply with study protocol and procedures and able to speak English.
- Willing to provide written informed consent.
You may not qualify if:
- Reinseminated eggs.
- History of cancer.
- Gestational carriers.
- Planned preimplantation genetic diagnosis or preimplantation genetic screening.
- Previously enrolled in this study
- Concurrent participation in another clinical study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Progyny, Inc.lead
Study Sites (3)
Pacific Fertility Center
San Francisco, California, 94133, United States
Fertility Physicians of Northern California
San Jose, California, 95124, United States
Reproductive Science Center
San Ramon, California, 94583, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Shehua Shen, ELD, MD
Progyny, Inc.
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 8, 2012
First Posted
June 13, 2012
Study Start
June 1, 2012
Primary Completion
February 1, 2013
Study Completion
February 1, 2013
Last Updated
January 13, 2014
Record last verified: 2014-01